Avenue Therapeutics Reaches Final Agreement with FDA For Phase 3 Safety Study For IV Tramadol
Portfolio Pulse from Benzinga Newsdesk
Avenue Therapeutics has finalized an agreement with the FDA on the Phase 3 safety study protocol for IV tramadol, aimed at treating acute post-operative pain. The study will compare the risk of opioid-induced respiratory depression between IV tramadol and IV morphine.
January 04, 2024 | 1:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Avenue Therapeutics has reached a final agreement with the FDA for a Phase 3 safety study of IV tramadol, which could positively impact the company's prospects if the study is successful.
Finalizing the Phase 3 study protocol with the FDA is a significant step forward for Avenue Therapeutics, indicating progress in the drug's development pathway. Positive results from the study could lead to eventual approval and commercialization, which would be a major catalyst for the company's stock. However, the actual impact will depend on the outcomes of the study.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100